Short answer
Lexeo Therapeutics, Inc. (LXEO) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$20M
- +38.2% YoY
- EPS (diluted)
- −$0.25
- +74.7% YoY
Source: XBRL data from the Lexeo Therapeutics, Inc. (LXEO) Q1 2026 10-Q on SEC EDGAR. USD.
Lexeo Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added administration risk: FDA and other agency actions could hinder hiring, leadership retention, or timely product commercialization
- Regulatory risk: Changing gene-therapy requirements create uncertain approval timing and costs across the United States, European Union, and other jurisdictions
- Operational risk: AAVrh10 development may face unforeseen toxicity, administration challenges, and delays achieving scalable production
- Financial risk: $227.6 million in cash, equivalents, and U.S. Treasury investments projected to fund operations into 2028
- Loss risk: $20.2 million quarterly net loss and $400.3 million accumulated deficit as of March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lexeo Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.